OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Stock Short Interest Report for October

Key Points

• Short interest more than doubled in October, rising 121.3% to 76,652 shares as of October 15, representing approximately 0.2% of OKYO Pharma’s outstanding stock.
• Analyst sentiment remains mixed but leans positive: three analysts rate the stock Buy and one rates it Sell, producing a consensus “Moderate Buy” rating and an average price target of $5.67.
• OKYO shares fell 3.3% to $1.45, while hedge fund Opaleye Management disclosed a new 375,204-share position worth about $563,000; institutional investors and hedge funds collectively own 2.97% of the company.

OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO - Get Free Report) saw a large growth in short interest in the month of October. As of October 15th, there was short interest totaling 76,652 shares, a growth of 121.3% from the September 30th total of 34,643 shares. Approximately 0.2% of the company's stock are short sold. Based on an average daily trading volume, of 42,929 shares, the short-interest ratio is currently 1.8 days.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on OKYO shares. HC Wainwright restated a "buy" rating on shares of OKYO Pharma in a research note on Wednesday, October 7th. Weiss Ratings restated a "sell (d-)" rating on shares of OKYO Pharma in a report on Thursday, October 15th. Three investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. According to MarketBeat, OKYO Pharma presently has a consensus rating of "Moderate Buy" and an average price target of $5.67.

OKYO Pharma Stock Down 3.3%

Shares of NASDAQ:OKYO traded down $0.05 during trading on Friday, hitting $1.45. 97,439 shares of the company were exchanged, compared to its average volume of 136,501. The business's 50 day moving average is $1.44 and its 200-day moving average is $1.64. OKYO Pharma has a 1-year low of $1.26 and a 1-year high of $3.20.

Hedge Funds Weigh In On OKYO Pharma

A hedge fund recently bought a new position in OKYO Pharma stock. Opaleye Management Inc. acquired a new position in OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO - Free Report) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 375,204 shares of the company's stock, valued at approximately $563,000. Opaleye Management Inc. owned 0.71% of OKYO Pharma as of its most recent filing with the Securities and Exchange Commission. 2.97% of the stock is currently owned by institutional investors and hedge funds.

About OKYO Pharma

OKYO Pharma Limited NASDAQ: OKYO is a clinical-stage biopharmaceutical company focused on developing precision medicines for inflammatory, ocular and pain-related diseases. The company's research is centered on G protein-coupled receptors (GPCRs), a broad class of biological targets involved in regulating immune responses, pain signaling and other disease processes.

OKYO's lead development program, OK-101, is a novel GPCR-targeting therapeutic being investigated for conditions including dry eye disease and neuropathic pain.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.